Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's disease

Journal of the Neurological Sciences

Volumn 337, Issue 1-2, 2014, Pages 47-54

  Jang, Wooyoung ^a,b   Park, Jinse ^c   Shin, Kyung Jin ^c   Kim, Joong Seok ^d   Kim, Ji Sun ^e   Youn, Jinyoung ^f   Cho, Jin Whan ^f   Oh, Eungseok ^g   Ahn, Jin Young ^h   Oh, Ki Wook ^b   Kim, Hee Tae ^b  

^a University of Ulsan   (South Korea)

^b Hanyang University   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d The Catholic University of Korea College of Medicine   (South Korea)

^e Soonchunhyang University   (South Korea)

^f Sungkyunkwan University   (South Korea)

^g Chungnam National University College of Medicine   (South Korea)

^h Seoul Medical Center   (South Korea)

Author keywords

Efficacy; Erythropoietin; Non motor symptoms; Parkinson's disease; PET; Safety

Indexed keywords

EFFICACY; ERYTHROPOIETIN; NON-MOTOR SYMPTOMS; PARKINSON'S DISEASE; PET; SAFETY;

AGED; AGED, 80 AND OVER; BRAIN; COGNITION DISORDERS; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; QUESTIONNAIRES; SINGLE-BLIND METHOD; SLEEP DISORDERS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TROPANES; VASCULAR DISEASES;

EID: 84894097671     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2013.11.015     Document Type: Article

References (57)

1. K.R. Chaudhuri, D.G. Healy, and A.H.V. Schapira Non-motor symptoms of Parkinson's disease: diagnosis and management Lancet Neurol 5 2006 235 245
2. K.R. Chaudhuri, C. Prieto-Jurcynska, Y. Naidu, T. Mitra, B. Frades-Payo, and S. Tluk et al. The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire Mov Disord 25 2010 704 709
3. H.-J. Kim, S.-Y. Park, Y.-J. Cho, K.-S. Hong, J.-Y. Cho, and S.-Y. Seo et al. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment J Neurol Sci 287 2009 200 204
4. J.M. Nazzaro, R. Pahwa, and K.E. Lyons The impact of bilateral subthalamic stimulation on non-motor symptoms of Parkinson's disease Parkinsonism Relat Disord 17 2011 606 609
5. H. Ehrenreich, M. Hasselblatt, C. Dembowski, L. Cepek, P. Lewczuk, and M. Stiefel et al. Erythropoietin therapy for acute stroke is both safe and beneficial Mol Med 8 2002 495 505
6. M. Sakanaka, T.-C. Wen, S. Matsuda, S. Masuda, E. Morishita, and M. Nagao et al. In vivo evidence that erythropoietin protects neurons from ischemic damage Proc Natl Acad Sci 95 1998 4635 4640
7. T. Shingo, S.T. Sorokan, T. Shimazaki, and S. Weiss Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells J Neurosci 21 2001 9733 9743
8. N.M. Kanaan, T.J. Collier, D.M. Marchionini, S.O. McGuire, M.F. Fleming, and C.E. Sortwell Exogenous erythropoietin provides neuroprotection of grafted dopamine neurons in a rodent model of Parkinson's disease Brain Res 1068 2006 221 229
9. A.P. Signore, Z. Weng, T. Hastings, A.D. Van Laar, Q. Liang, and Y.J. Lee et al. Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death J Neurochem 96 2006 428 443
10. B. Adamcio, D. Sargin, A. Stradomska, L. Medrihan, C. Gertler, and F. Theis et al. Erythropoietin enhances hippocampal long-term potentiation and memory BMC Biol 6 2008 37
11. M. Yamamoto, K. Koshimura, M. Kawaguchi, M. Sohmiya, Y. Murakami, and Y. Kato Stimulating effect of erythropoietin on the release of dopamine and acetylcholine from the rat brain slice Neurosci Lett 292 2000 131 133
12. G. Lauria, A. Campanella, G. Filippini, A. Martini, P. Penza, and L. Maggi et al. Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability Amyotroph Lateral Scler 10 2009 410 415
13. H. Ehrenreich, B. Fischer, C. Norra, F. Schellenberger, N. Stender, and M. Stiefel et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis Brain 130 2007 2577 2588
14. H. Ehrenreich, D. Hinze-Selch, S. Stawicki, C. Aust, S. Knolle-Veentjer, and S. Wilms et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin Mol Psychiatry 12 2007 206 220
15. H. Ehrenreich, K. Weissenborn, H. Prange, D. Schneider, C. Weimar, and K. Wartenberg et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke Stroke 40 2009 e647 e656
16. K. Miskowiak, B. Inkster, U. O'Sullivan, S. Selvaraj, G. Goodwin, and C. Harmer Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration Exp Brain Res 184 2008 313 321
17. K. Miskowiak, B. Inkster, S. Selvaraj, R. Wise, G.M. Goodwin, and C.J. Harmer Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration Neuropsychopharmacology 33 2007 611 618
18. K.W. Miskowiak, M. Vinberg, C.J. Harmer, H. Ehrenreich, G.M. Knudsen, and J. Macoveanu et al. Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder Trials 11 2010 97
19. K.-W. Sühs, K. Hein, M.B. Sättler, A. Görlitz, C. Ciupka, and K. Scholz et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis Ann Neurol 72 2012 199 210
20. I. Pedroso, M.L. Bringas, A. Aguiar, L. Morales, M. Alvarez, and P.A. Valdés et al. Use of Cuban recombinant human erythropoietin in Parkinson's disease treatment MEDICC Rev 14 2012 11 17
21. A.J. Hughes, S.E. Daniel, L. Kilford, and A.J. Lees Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 1992 181 184
22. C.G. Goetz, S. Fahn, P. Martinez-Martin, W. Poewe, C. Sampaio, and G.T. Stebbins et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan Mov Disord 22 2007 41 47
23. M.M. Hoehn, and M.D. Yahr Parkinsonism: onset, progression and mortality Neurology 17 1967 427 442
24. K.R. Chaudhuri, P. Martinez-Martin, R.G. Brown, K. Sethi, F. Stocchi, and P. Odin et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study Mov Disord 22 2007 1901 1911
25. U. Krikmann, P. Taba, T. Lai, and T. Asser Validation of an Estonian version of the Parkinson's Disease Questionnaire (PDQ-39) Health Qual Life Outcomes 6 2008 23
26. H.K. Park, J.S. Kim, K.C. Im, S.J. Oh, M.J. Kim, and J.-H. Lee et al. Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and [18F] FP-CIT PET analyses Mov Disord 24 2009 237 245
27. G. Singbartl Adverse events of erythropoietin in long-term and in acute/short-term treatment Clin Investig 72 1994 S36 S43
28. D.E. Hobson, A.E. Lang, W. Martin, A. Razmy, J. Rivest, and J. Fleming Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group JAMA 287 2002 455 463
29. S.A. Lipton Erythropoietin for neurologic protection and diabetic neuropathy N Engl J Med 350 2004 2516 2517
30. P. Martinez-Martin, C. Rodriguez-Blazquez, M.M. Kurtis, K.R. Chaudhuri on Behalf of the NVG The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease Mov Disord 26 2011 399 406
31. A.M. Bonnet, M.F. Jutras, V. Czernecki, J.C. Corvol, and M. Vidailhet Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects Park Dis 2012 2012 15
32. K.R. Chaudhuri, and A.H.V. Schapira Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment Lancet Neurol 8 2009 464 474
33. K. Kujawa, S. Leurgans, R. Raman, L. Blasucci, and C.G. Goetz Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease Arch Neurol 57 2000 1461 1463
34. S. Wishart, and G.J. Macphee Evaluation and management of the non-motor features of Parkinson's disease Ther Adv Chronic Dis 2 2011 69 85
35. G.F. Benderro, X. Sun, Y. Kuang, and J.C. Lamanna Decreased VEGF expression and microvascular density, but increased HIF-1 and 2α accumulation and EPO expression in chronic moderate hyperoxia in the mouse brain Brain Res 1471 2012 46 55
36. E.A. Dale, I. Satriotomo, and G.S. Mitchell Cervical spinal erythropoietin induces phrenic motor facilitation via extracellular signal-regulated protein kinase and Akt signaling J Neurosci 32 2012 5973 5983
37. P.G. Keddy, K. Dunlop, J. Warford, M.L. Samson, Q.R. Jones, and H.P. Rupasinghe et al. Neuroprotective and anti-inflammatory effects of the flavonoid-enriched fraction AF4 in a mouse model of hypoxic-ischemic brain injury PLoS One 7 2012 e51324
38. E.C. Wolters Non-motor extranigral signs and symptoms in Parkinson's disease Parkinsonism Relat Disord 15 2009 S6 S12
39. J. Jankovic, and A.S. Kapadia Functional decline in Parkinson disease Arch Neurol 58 2001 1611 1615
40. P.S. Group A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD study Clin Neuropharmacol 23 2000 34 44
41. A.L. Whone, R.L. Watts, A.J. Stoessl, M. Davis, S. Reske, and C. Nahmias et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study Ann Neurol 54 2003 93 101
42. R.D. Hoeldtke, G.G. Horvath, and K.D. Bryner Treatment of orthostatic tachycardia with erythropoietin Am J Med 99 1995 525 529
43. R.D. Hoeldtke, and D. Streeten Treatment of orthostatic hypotension with erythropoietin N Engl J Med 329 1993 611 615
44. K. Kanjwal, B. Saeed, B. Karabin, Y. Kanjwal, M. Sheikh, and B.P. Grubb Erythropoietin in the treatment of postural orthostatic tachycardia syndrome Am J Ther 19 2012 92 95
45. K. Kawakami, H. Abe, N. Harayama, and Y. Nakashima Successful treatment of severe orthostatic hypotension with erythropoietin Pacing Clin Electrophysiol 26 2003 105 107
46. R.L. Benz, M.R. Pressman, E.T. Hovick, and D.D. Peterson A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (the SLEEPO study) Am J Kidney Dis 34 1999 1089 1095
47. F. GarcÍa-GarcÍa, and J.M. Krueger Intracerebroventricular injection of erythropoietin enhances sleep in the rat Brain Res Bull 61 2003 541 546
48. D.C. Harris, J.R. Chapman, J.H. Stewart, S. Lawrence, and S.D. Roger Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis Aust N Z J Med 21 1991 693 700
49. K. Miskowiak, M. Vinberg, C. Harmer, H. Ehrenreich, and L. Kessing Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression Psychopharmacology (Berl) 219 2012 687 698
50. A. Weber, R.F. Maier, U. Hoffmann, M. Grips, M. Hoppenz, and A.G. Aktas et al. Erythropoietin improves synaptic transmission during and following ischemia in rat hippocampal slice cultures Brain Res 958 2002 305 311
51. A.R. Nissenson Epoetin and cognitive function Am J Kidney Dis 20 1992 21 24
52. Y.W. Wu, L.A. Bauer, R.A. Ballard, D.M. Ferriero, D.V. Glidden, and D.E. Mayock et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics Pediatrics 130 2012 683 691
53. R. Kumar, A.S. Jaggi, and N. Singh Effects of erythropoietin on memory deficits and brain oxidative stress in the mouse models of dementia Korean J Physiol Pharmacol 14 2010 345 352
54. S.-T. Lee, K. Chu, J.-E. Park, K.-H. Jung, D. Jeon, and J.-Y. Lim et al. Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer's disease models J Neurochem 120 2012 115 124
55. W.M. Campana, and R.R. Myers Exogenous erythropoietin protects against dorsal root ganglion apoptosis and pain following peripheral nerve injury Eur J Neurosci 18 2003 1497 1506
56. H. Resic, A. Alajbegovic, V. Sahovic, E. Suljic, E. Mesic, and R. Javoric Effect of erythropoietin on gonadotropic hormones and sexual function in patients on hemodialysis Med Arh 58 2004 113 115
57. R. Bianchi, A. Gilardini, V. Rodriguez-Menendez, N. Oggioni, A. Canta, and T. Colombo et al. Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth Eur J Cancer 43 2007 710 717